依洛尤单抗联合瑞舒伐他汀对冠心病合并血脂异常患者脂质代谢指标及心功能的影响OA

Objective:To investigate the effects of evolocumab combined with rosuvastatin on lipid metabolism indices and cardiac function in patients with coronary heart disease(CHD)and hyperlipidemia.Methods:This prospective randomized controlled trial enrolled 124 patients with CHD and hyperlipidemia treated at a hospital from July 2022 to July 2024.Using a random number table method,the patients were assigned to a control group receiving rosuvastatin or an observation group receiving evolocumab plus rosuvastatin,with 62 cases in each group.Changes from before to after treatment in serum lipid parameters[low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C),and total cholesterol(TC)],lipid metabolism indices[apolipoprotein(Apo)A1 and ApoB],and cardiac function parameters[left ventricular ejection fraction(LVEF)and left ventricular end-diastolic diameter(LVEDD)],as well as the incidences of major adverse cardiovascular event(MACE)and adverse reactions were compared between the groups.Results:After treatment,LDL-C,TC,ApoB,and LVEDD were decreased in both groups and were lower in the observation group than those in the control group(P<0.05).HDL-C,ApoA1,and LVEF were increased in both groups and were higher in the observation group compared with those in the control group(P<0.05).No statistical differences were exhibited in the overall incidence of MACE and overall incidence of adverse reactions between the two groups(P>0.05).Conclusion:Evolocumab combined with rosuvastatin effectively improves serum lipids and lipid metabolism indices and further improves cardiac function in patients with CHD and hyperlipidemia without increasing the risk of adverse drug reactions.